Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year

“During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart,” said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “For VG-3927, we reported positive Phase 1 data in January 2025 that support the planned initiation of a Phase 2 trial in Alzheimer’s disease patients in Q3. We also presented these findings at the AD/PD scientific conference, further highlighting VG-3927’s potential as a differentiated next-generation therapeutic candidate for the treatment of AD. Additionally, we have remained focused on advancing iluzanebart through the final stages of the Phase 2 trial in ALSP, with the full data readout on track for Q2. With continued momentum across both programs, we are well-positioned to deliver on key clinical milestones in 2025 that will support our commitment and mission to bring these potentially transformative therapies to patients and their families.”